Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Linclatamig |
| Synonyms | |
| Therapy Description |
Linclatamig (BLYG8824A) is a bispecific T-cell engager targeting LY6G6D and CD3, which potentially induces antitumor activity (Cancer Res (2025) 85 (8_Supplement_2): CT157). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Linclatamig | BLYG 8824A|BLYG-8824A|BLYG8824A | CD3 Antibody 119 | Linclatamig (BLYG8824A) is a bispecific T-cell engager targeting LY6G6D and CD3, which potentially induces antitumor activity (Cancer Res (2025) 85 (8_Supplement_2): CT157). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04468607 | Phase I | Linclatamig | A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer | Completed | USA | ESP | AUS | 0 |